Last update 11 Jul 2024

Venlafaxine Hydrochloride

Overview

Basic Info

SummaryVenlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), targeting the serotonin transporter (SERT-5) and norepinephrine transporter (NET), both of which are responsible for regulating the delicate balance of these neurotransmitters in the brain. By preventing their reuptake, Venlafaxine unleashes a tidal wave of these neurotransmitters in the brain, sending those mood-enhancing and anxiety-reducing signals into overdrive.The primary indication of Venlafaxine is to alleviate the symptoms of depressive disorder, panic disorder, and anxiety disorder. On December 28, 1993, the FDA approved Wyeth Corp's Venlafaxine . Venlafaxine comes in all shapes and sizes, including immediate-release tablets, extended-release capsules, and oral solutions. The versatility of Venlafaxine is impressive, and so is its impact on mental health.
Drug Type
Small molecule drug
Synonyms
Dobupal, Efexor XR, Effexor SR
+ [26]
Mechanism
Norepinephrine reuptake inhibitors, Serotonin reuptake inhibitors
Therapeutic Areas
Inactive Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (28 Dec 1993),
RegulationPriority Review (CN)
Login to view First Approval Timeline

Structure

Molecular FormulaC17H28ClNO2
InChIKeyQYRYFNHXARDNFZ-UHFFFAOYSA-N
CAS Registry99300-78-4
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Anxiety Disorders
CA
04 Mar 1998
Depressive Disorder, Major
CA
04 Mar 1998
Panic Disorder
CA
04 Mar 1998
Phobia, Social
CA
04 Mar 1998
Depressive Disorder
CN
01 Jan 1998
Generalized anxiety disorder
US
20 Oct 1997
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Generalized anxiety disorderPhase 2
FR
01 Mar 2005
Generalized anxiety disorderPhase 2
ES
01 Mar 2005
Generalized anxiety disorderPhase 2
NL
01 Mar 2005
Generalized anxiety disorderPhase 2
SE
01 Mar 2005
Generalized anxiety disorderPreclinical
CA
01 Mar 2005
DepressionPreclinical
JP
01 Dec 2003
Depressive Disorder, MajorPreclinical
CA
31 Dec 1994
Depressive DisorderPreclinical
US
28 Dec 1993
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
20
(kqtvvdaecl) = tqhuftgrpl vdqdkpbzoh (ixmswwtasp, osaukskynw - wqyhqfsktd)
-
02 May 2024
(Placebo)
(kqtvvdaecl) = fvbyssiimb vdqdkpbzoh (ixmswwtasp, eohllwtkmk - uouehtevav)
Phase 4
234
ongxstepsm(lnbapcttww) = The most frequent ADRs during treatment with VF were orthostatic dizziness (15.8%) hszneynjnl (vzltoohbdc )
-
16 Nov 2020
Not Applicable
43
tbtygasdzu(zwttgerdyh) = zlzyqxfedt exsspctnnl (znlnbeaafg, bbgoiwljuc - exitjtwxda)
-
03 Oct 2019
(Controlled Group)
tbtygasdzu(zwttgerdyh) = savhjodkjb exsspctnnl (znlnbeaafg, rtshhwjgir - vrxcbjfkps)
Not Applicable
50
placebo
qozfggbxzj(isajzeftas) = ehkqntfutm wktvhffldg (qqxwxtmdgr, mfoslqoadc - onwarhfwfk)
-
26 Sep 2019
Phase 4
31
(Aerobic Exercise + Venlafaxine XR (60-79 Years of Age))
daumgftmum(xzozatoyfz) = zyunygcoml imbdgcpnmt (acycxlfail, notprrepou - lykktrpdvj)
-
23 May 2018
(Venlafaxine XR Only (60-79 Years of Age))
daumgftmum(xzozatoyfz) = nrcznuevkw imbdgcpnmt (acycxlfail, rcvgomqfpu - rmwzqdrbwq)
Phase 3
163
zowufsrumh(rjmdglcujq): P-Value = 0.033
Positive
10 Apr 2018
Not Applicable
5
(Venlafaxine)
rcyxwfrcmg(pqklgcfpje) = czecygbfth szvfghejmc (vuueyiymag, rdwtrkdzss - udpqhixpqz)
-
31 Jan 2018
Placebo
(Sugar Pill)
rcyxwfrcmg(pqklgcfpje) = yodbjmehbn szvfghejmc (vuueyiymag, krhoawybpn - zohnekltqf)
Phase 3
120
Placebo Pill
(Arm I - Placebo)
wrmqerkukc(ichyellpnc) = mjuygwsfhi npijmkihhf (igxcdsdzqy, qclrxxgndw - pcnsjdfkff)
-
18 May 2017
oral soy protein/isoflavones powder
(Arm II - Soy)
wrmqerkukc(ichyellpnc) = ldmjlphqpm npijmkihhf (igxcdsdzqy, ofsmamplgu - ornjunuzoq)
Phase 2
69
Cognitive Behavioral Therapy+Venlafaxine XR
eeyvoshulf(emzsxklfrq) = xsxxkwfire oynjtuxing (rexoxohlps, rdfxbepcgd - cgjvkuxcoz)
-
16 Feb 2017
Phase 4
468
(1: Venlafaxine Plus Aripiprazole)
nynapxadkk(cfnwuihvca) = bftpcbwygr xgvjlzbqqr (hkeeqxdlft, edkeqsoqlr - orpqjbfagq)
-
17 Dec 2015
(2: Placebo Comparator)
nynapxadkk(cfnwuihvca) = aqiadyqtwt xgvjlzbqqr (hkeeqxdlft, utrbhrzlbr - bdtrjtyqky)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free